Codeine, Phenylephrine and Promethazine Combination

Codeine Phosphate; Phenylephrine Hydrochloride; Promethazine Hydrochloride Overview

Managing complex upper respiratory tract conditions characterized by persistent cough, nasal congestion, and histamine-mediated mucosal irritation requires a targeted multi-ingredient approach. The fixed-dose combination of Codeine Phosphate, Phenylephrine Hydrochloride, and Promethazine Hydrochloride is an FDA-approved oral syrup. Used across general medicine, pulmonology, and primary care, this triple-action prescription medication provides temporary relief of cough, nasal congestion, and upper respiratory allergic or cold symptoms in adult patients.

What Is Codeine, Phenylephrine, and Promethazine and How Does It Work?

This triple-combination product delivers multi-symptom upper respiratory relief through three distinct, synergistic mechanisms of action:

Codeine phosphate is a semi-synthetic opioid agonist that acts centrally on the medullary cough center within the brainstem. By binding to mu-opioid receptors, it raises the threshold for the cough reflex, effectively suppressing non-productive coughing spasms associated with upper respiratory tract infections or allergies.

Is Codeine, Phenylephrine, and Promethazine FDA Approved?

Yes, Codeine Phosphate, Phenylephrine Hydrochloride, and Promethazine Hydrochloride Oral Syrup is fully FDA approved. The combination received its formal regulatory approval under application NDA 008804  in (December 2006) and serves as a regulated prescription therapeutic option.

What Is Codeine, Phenylephrine, and Promethazine Used For?

• Multi-Symptom Cold and Allergy Relief: Temporary relief of cough, nasal congestion, and upper respiratory allergic symptoms (such as rhinorrhea, sneezing, and itchy, watery eyes) associated with allergic rhinitis or viral upper respiratory tract infections in adults.

Before Taking Codeine, Phenylephrine, and Promethazine: Contraindications & Precautions

Because this product contains an opioid, a sympathomimetic decongestant, and a sedating phenothiazine, thorough screening for age, respiratory, cardiovascular, and neurological risk factors is mandatory.

Who Should Not Take This Combination?

• Pediatric Patients Under 18 Years of Age: Strictly contraindicated in all children and adolescents under 18 years of age due to risks of severe, life-threatening, or fatal respiratory depression.
• Post-Tonsillectomy or Adenoidectomy: Strictly contraindicated for post-operative pain or cough management in pediatric patients who have undergone tonsillectomy or adenoidectomy.
• Significant Respiratory Depression: Contraindicated in patients with acute or severe bronchial asthma, hypercarbia, chronic obstructive pulmonary disease (COPD), or severe respiratory compromise.
• Monoamine Oxidase Inhibitor (MAOI) Therapy: Strictly contraindicated in patients taking MAOIs or within 14 days of discontinuing MAOI therapy due to risks of fatal hypertensive crisis, serotonin syndrome, or severe CNS collapse.
• Severe Cardiovascular Disease: Contraindicated in patients with severe uncontrolled hypertension, severe coronary artery disease, or lethal cardiac dysrhythmias.
• Lower Respiratory Tract Disease: Contraindicated in patients with lower respiratory tract symptoms, including acute asthma attacks, where anticholinergic actions can cause bronchial secretion thickening.

Pregnancy, Fertility & Lactation

Codeine and promethazine carry significant pregnancy precautions. Prolonged maternal use of codeine during pregnancy can cause neonatal opioid withdrawal syndrome (NOWS), a life-threatening condition requiring specialized neonatal ICU care. Codeine is ultra-rapidly metabolized by CYP2D6 into morphine; breastfed infants of ultra-rapid metabolizer mothers are at high risk of fatal respiratory depression. Breastfeeding while taking this medication is strictly contraindicated.

Tell Your Doctor Before Taking This Medication

Patients must disclose a complete clinical history before starting treatment. Inform your doctor if you have a history of substance use disorder, alcoholism, head injury, elevated intracranial pressure, seizure disorders, asthma, COPD, hypertension, coronary artery disease, hyperthyroidism, diabetes, narrow-angle glaucoma, prostatic hypertrophy, or hepatic/renal impairment. Disclose all concurrent medications, particularly central nervous system depressants, sedatives, tranquilizers, anticholinergic drugs, or antihypertensives.

Codeine, Phenylephrine, and Promethazine Dosage & Administration

This multi-symptom liquid syrup is formulated strictly for oral administration using a calibrated measuring device in adult patients.

Standard Adult Dosing (18 Years and Older)

• Standard Adult Dose: 5 mL (containing 10 mg codeine phosphate, 5 mg phenylephrine hydrochloride, and 6.25 mg promethazine hydrochloride) taken orally every 4 to 6 hours as needed while symptoms persist.
• Maximum Recommended Daily Dose: Do not exceed 30 mL (6 doses) within a 24-hour period.
• Pediatric Dosing: Strictly contraindicated in patients under 18 years of age.

How to Take This Medication

• Use a Calibrated Device: Measure doses strictly with a calibrated oral syringe or dosing cup provided by the pharmacy. Do not use household teaspoons or tablespoons, as this leads to inaccurate dosing and risk of toxicity.
• Can be taken with or without food. Taking with food or milk can help minimize mild gastrointestinal upset.
• Shortest Duration Principle: Use the lowest effective dose for the shortest duration possible to minimize risks of addiction, dependence, and adverse events.

Codeine, Phenylephrine, and Promethazine Clinical Efficacy & Research

Clinical evaluations of combination antitussive, decongestant, and antihistamine formulations confirm that multi-ingredient liquid products provide superior overall relief for complex upper respiratory conditions compared to single-agent options. Codeine significantly elevates the threshold for the central cough reflex, reducing cough frequency over 4 to 6 hours. Simultaneously, phenylephrine reduces nasal mucosal hyperemia and airway resistance, while promethazine decreases histamine-driven rhinorrhea, sneezing, and lacrimation, providing combined therapeutic action for adult upper respiratory conditions.

Codeine, Phenylephrine, and Promethazine Side Effects & Safety Profile

The adverse event profile reflects the combined safety profiles of its three active components, encompassing central nervous system, cardiovascular, and anticholinergic effects.

• Risk of Addiction, Abuse, and Misuse: Codeine is an opioid that exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death.
• Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression may occur. Ultra-rapid metabolizers of codeine (via CYP2D6) are at heightened risk of respiratory arrest.
• Accidental Ingestion: Accidental ingestion of even one dose, especially by children, can result in a fatal codeine overdose.
• Risks from Concomitant Use with Benzodiazepines or CNS Depressants: Co-administration with benzodiazepines, alcohol, or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
• Promethazine Pediatric Risk: Promethazine can cause fatal respiratory depression in pediatric populations.
• Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome.

Common Side Effects (>10%)

• Profound drowsiness, sedation, somnolence, or fatigue.
• Dizziness, lightheadedness, or feeling unsteady.
• Dryness of the mouth, nose, and throat.
• Constipation, nausea, or mild stomach upset.

Serious Adverse Events

• Severe, life-threatening respiratory depression or respiratory arrest.
• Cardiovascular complications: significant hypertension, sinus tachycardia, palpitations, severe hypotension, or syncope.
• Neuroleptic Malignant Syndrome (NMS) or extrapyramidal symptoms (dystonia, tardive dyskinesia) associated with promethazine.
• Central nervous system depression, stupor, coma, or seizures.
• Severe allergic reactions: anaphylaxis, angioedema, or severe cutaneous rash.
• Genitourinary impairment: acute urinary retention or dysuria.

Managing Side Effects

If mild drowsiness or dizziness occurs, avoid driving or operating heavy machinery. Increase fluid and fiber intake to help prevent opioid-induced constipation. If slow or shallow breathing, severe dizziness, inability to stay awake, rapid heartbeat, or signs of an allergic reaction develop, discontinue the medication immediately and seek emergency medical care. Naloxone should be available as a reversal agent for severe codeine toxicity.

Codeine, Phenylephrine, and Promethazine Drug Interactions & What to Avoid

Interactions with this combination involve severe additive central nervous system depression, cardiovascular stimulation, and altered metabolic clearance.

Drug-Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs or within 14 days of stopping them is strictly contraindicated due to risks of fatal hypertensive crisis, hyperpyrexia, or CNS collapse.
• Benzodiazepines, Sedatives, Opioids, and CNS Depressants: Co-administration produces additive CNS depression, respiratory depression, profound sedation, coma, and death.
• CYP2D6 Inhibitors (Fluoxetine, Paroxetine, Quinidine): Alter codeine conversion to its active metabolite (morphine), blunting efficacy or causing unpredictable plasma levels.
• Anticholinergic Drugs (Atropine, Tricyclic Antidepressants): Potentiates anticholinergic side effects, increasing risks of paralytic ileus, severe dry mouth, urinary retention, and constipation.
• Antihypertensives and Diuretics: Phenylephrine directly opposes blood pressure-lowering effects of antihypertensive agents.

Alcohol Warning

Avoid all alcohol and alcohol-containing medications. Consuming alcohol with this product produces additive, potentially fatal central nervous system and respiratory depression, while worsening motor impairment and sedation.

Codeine, Phenylephrine, and Promethazine: Missed Dose, Overdose & Storage

Missed Dose

If you miss a dose, take it as soon as you remember, provided it is not close to your next scheduled dose. If it is nearly time for your next dose, skip the missed dose and resume your 4 to 6 hour schedule. Do not double up doses or take extra medicine to make up for a missed dose.

Overdose & Emergency

Overdosage manifests as mixed toxicity involving opioid, sympathomimetic, and anticholinergic features. Symptoms include pinpoint pupils (or dilated pupils in severe promethazine toxicity), severe somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, severe hypertension or rebound hypotension, severe tachycardia, cardiac dysrhythmias, tremors, seizures, and life-threatening respiratory depression. In case of suspected overdose, seek immediate emergency medical treatment or call a poison control center. Immediate administration of intravenous naloxone and supportive respiratory care are required.

Storage Instructions

Store syrup at controlled room temperature between 20 degrees Celsius and 25 degrees Celsius (68 degrees Fahrenheit to 77 degrees Fahrenheit). Protect from light and freezing. Keep the bottle tightly closed in its original container. Store securely in a locked cabinet away from children, visitors, and pets to prevent theft, abuse, or accidental ingestion. Properly dispose of unused medication through an authorized drug take-back program.

Codeine, Phenylephrine, and Promethazine Patient Management & Monitoring

Safe clinical therapy requires verifying patient age, screening for addiction and respiratory risk factors, and ensuring accurate liquid measuring.

Clinical Assessment Before Starting Treatment

• Evaluation of history for substance use disorder, asthma, COPD, or respiratory failure.
• Screening for recent MAOI use, severe hypertension, or cardiovascular disease.
• Verification of patient age to confirm the patient is 18 years of age or older.

Monitoring During Treatment

• Monitoring respiratory status, blood pressure, pulse rate, and level of consciousness.
• Observing for signs of misuse, abuse, addiction, or excessive sedation.
• Assessing for signs of anticholinergic toxicity or urinary retention.

Do’s and Don’ts

• DO use an accurate calibrated measuring syringe or cup provided by your pharmacist.
• DO store securely in a locked location out of reach of children.
• DON’T administer to anyone under 18 years of age.
• DON’T use a household spoon to measure liquid doses.
• DON’T consume alcohol or take non-prescribed sedating medications while using this drug.

Frequently Asked Questions

References

• U.S. FDA Label Information for Promethazine Hydrochloride, Phenylephrine Hydrochloride, and Codeine Phosphate Oral Syrup.
• U.S. FDA Drugs@FDA – Application Number: NDA 008804 , Initial Approval Date: December 2006.

Legal Disclaimer

This educational document is intended for informational purposes only and does not substitute for formal medical advice, clinical diagnosis, or specialized treatment. Always consult a qualified physician, pulmonologist, or pharmacist with specific questions regarding persistent cough, prescription opioids, or controlled drug administration.